According to World Health Organization (WHO), raised blood pressure is estimated to cause 7.5 million deaths around the world. Hypertension is a risk factor for coronary heart disease, ischemic and hemorrhagic stroke. In addition complications of hypertension includes peripheral vascular disease, heart failure, renal impairment, retinal hemorrhage and visual impairment.
Having family history of Pulmonary Arterial Hypertension, change in life style, unhealthy food, and physical inactivity causes hypertension.
To treat pulmonary atrial hypertension following treatments are available
Medications include blood vessel dilators (vasodilators), Endothelin receptor antagonists, phosphodiesterase III inhibitors, calcium channel blockers, anticoagulants, diuretics.
Atrial septostomy and Transplantation are the two surgery option for patients who suffering from severe pulmonary atrial hypertension. Transplantation is may be an option for younger people who are suffering from idiopathic pulmonary hypertension.
Pulmonary Arterial Hypertension Treatment Market: Drivers and Restraints
According to World Health Organization, Globally the prevalence rate of hypertension was 40% in adults who aged 25 and above in the year 2008. The prevalence rate is high in Africa region and Americas having less prevalence rate in hypertension. Change in the life style, family history of pulmonary atrial hypertension, unhealthy food, and physical inactivity are the risk factors for hypertension as well as drivers for this market. Raising the geriatric population around the world also driver for pulmonary atrial hypertension treatment market. Guidelines form government organizations such as World Health Organization (WHO), Center for Disease Control and Prevention plays a major role in the prevention of pulmonary atrial hypertension treatment.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1218
Pulmonary Arterial Hypertension Treatment Market: Segmentation
Pulmonary Arterial Hypertension Treatment Market is segmented into following types:
- Based on Treatment
- Blood Vessel Dilators (Vasodilators)
- Endothelin Receptor Antagonists
- Phosphodiesterase III Inhibitors
- Calcium Channel Blockers
- Based on End User
- Drug store
- Hospital Pharmacies
Pulmonary Arterial Hypertension Treatment Market: Overview
With good awareness about healthcare among people and guidance from international organizations about the Pulmonary Arterial Hypertension Treatment, the market is expected to have a healthy growth in the forecast period (2016-2026)
Pulmonary Arterial Hypertension TreatmentMarket: Region- wise Outlook
Depending on geographic regions, the global Pulmonary Arterial Hypertension Treatment market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1218
Pulmonary Arterial Hypertension Treatment is high in North America because it is highly developed region, having good healthcare setup and people are having good awareness about health care. Asia Pacific is expected to grow at a remarkable CAGR. Europe also having good growth in this market.
Pulmonary Arterial Hypertension TreatmentMarket: Key Players
Some of the key players in this market are
- Pfizer inc.
- Bristol myers co
- Novartis AG.
- GlaxoSmithKline Pharmaceuticals Limited
- Dr. Reddy’s Laboratories Ltd.